Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 384 results for kidney

  1. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  2. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

  3. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    risk of conditions affecting the eyes and vision, the feet, nerves and kidneys. All of these could lead to complications that could...

  4. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

  5. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

    We have moved Diagnostics guidance 37 to become HealthTech guidance 530. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  6. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  7. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  8. Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower urinary tract dysfunction?

    urodynamic measures of bladder storage with the potential to protect the kidneys from the effects of high intravesical pressures. It is...

  9. Contrast-enhanced spectral mammography for breast cancer (MIB304)

    NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .

  10. COVID-19 rapid guideline: chronic kidney disease (NG176)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with chronic kidney disease see our guideline on assessing and managing chronic kidney disease and for people with COVID-19 see our guideline on managing COVID-19.

  11. Tegaderm CHG securement dressing for vascular access sites (MIB231)

    NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .

  12. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

    Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.

  13. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

  14. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  15. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.